key: cord-0845907-2rs3mo9w
authors: Nuche, Jorge; Pérez-Olivares, Carmen; Cal, Teresa Segura De La; López-Guarch, Carmen Jiménez; Ynsaurriaga, Fernando Arribas; Subías, Pilar Escribano
title: Clinical Course Of Covid-19 In Pulmonary Arterial Hypertension Patients
date: 2020-05-30
journal: Rev Esp Cardiol (Engl Ed)
DOI: 10.1016/j.rec.2020.05.015
sha: dfd3ea23b6c107f5616004b473ca77ea83746476
doc_id: 845907
cord_uid: 2rs3mo9w

nan

To the Editor,

The coronavirus disease of 2019 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). 1 Most patients with severe disease develop pneumonia and acute respiratory distress syndrome (ARDS). 1 Patients with previous cardiovascular conditions seem to be at a higher risk for developing severe forms of COVID-19. 1 Pulmonary arterial hypertension (PAH) is a rare disease with a poor long-term prognosis and a particularly high mortality risk during hospitalizations for noncardiovascular conditions. 2 By 10 April 2020, 10 We report the clinical characteristics and outcomes of PAH patients with COVID-19. The mortality risk from noncardiovascular processes for PAH patients was particularly high (9.4% for pneumonia, 21.4% for respiratory failure). 2 Surprisingly, half of our patients only developed mild symptoms and, among those with established pneumonia, a favorable course was the general trend, without need for intensive care or deaths.

We hypothesize that the physiopathological features of PAH and the benefits attributable to specific treatment might lead to a protective effect through the following mechanisms (figure 1):

− Angiotensin-converting enzyme 2 (ACE2): In PAH patients' blood and lungs, ACE2 expression is decreased. 3 Indeed, recombinant ACE2 has been proposed as a novel therapy for PAH, to reverse vasoconstriction, proliferation, and inflammation. 3 ACE2 is known to act as a receptor for SARS-CoV-2. Experimental studies with SARS-CoV have shown that in ACE2 knockout mice, only a very low quantity of infectious SARS-CoV virus could be recovered. 4 Thus, low ACE2 levels in PAH patients could act as a protective factor at an initial infective phase, avoiding SARS-Cov-2 entrance.

Chronic pulmonary inflammation is a common finding in PAH patients. 3, 5 The immune cell types that infiltrates the lungs of PAH patients include lymphocytes, macrophages, neutrophils, dendritic cells, and mast cells. This different immune cellular landscape in PAH lungs suggests a shift toward the adaptive immune system. Therefore, the so-called tertiary lymphoid tissue is present in the vicinity of bronchioles and could limit viral infection and expansion.

2. Attenuated lung damage: Changes in pulmonary circulation inherent to PAH pathophysiology or related to specific vasodilator treatment might reduce the damage inflicted to the lungs and the consequent severe hypoxemia described in COVID-19 patients.

− Changes in lung perfusion: An atypical form of ARDS has been described among COVID-19 patients. An unusual dissociation between lung mechanical properties (with nearly normal compliance) and severe hypoxemia has been reported, 6 suggesting abnormal hyperperfusion of nonventilated areas as a consequence of impaired lung perfusion regulation and hypoxic vasoconstriction. 6 The basal abnormal lung perfusion present in PAH patients could limit this abrupt perfusion imbalance toward nonventilated areas. Furthermore, chronic vasodilator 

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from

A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Current Pharmacological Approach to ARDS: The Place of Bosentan

Management of COVID-19 Respiratory Distress